Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot EbbinghausKeaven M. Anderson, Tara C. Gangadhar

Research output: Contribution to journalComment/debatepeer-review

8 Scopus citations

Abstract

In the original version of this article (1), the stated disclosure of Jedd D. Wolchok is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article.

Original languageEnglish (US)
Pages (from-to)6098
Number of pages1
JournalClinical Cancer Research
Volume24
Issue number23
DOIs
StatePublished - Dec 1 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)'. Together they form a unique fingerprint.

Cite this